Elan
Perrigo acquires Omega for $4.5 billion
November 7, 2014Manufacturing and Production, Sales and Marketing Actavis, Boehringer Ingelheim, Boehringer Ingelheim., Elan, Perrigo, Sanofi, omega
In a deal worth $4.5 billion Perrigo has announced the acquisition of over-the-counter (OTC) drugmaker Omega. This places the Irish …
Edelman buys Elan to ‘challenge’ the French PR industry
September 5, 2014Medical Communications, Sales and Marketing Edelman, Elan, publicis
Edelman has swooped in on fellow PR firm Elan to create a ‘new player’ in the communications industry in France. …
Questcor adds Elan president to its Board
November 15, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Elan, Questcor, martin
Biopharma firm Questcor Pharmaceuticals has appointed Elan’s president and chief executive G. Kelly Martin to its Board of directors. Martin has …
Perrigo pays $8.6 billion for Elan
July 30, 2013Research and Development, Sales and Marketing Elan, Perrigo, Tysabri
Generics firm Perrigo has snapped up Ireland-based Elan in a multi-billion dollar deal, ending a bitter takeover battle that has …
J&J sees Q2 sales rise
July 17, 2013Sales and Marketing Elan, J&J, JJ, Q2, Synthes, sales
Johnson & Johnson saw overall sales rise 8.5% year-on-year in the second quarter of 2013, with the US healthcare group …
Elan signs $1 billion finance deal with Theravance
May 15, 2013Research and Development, Sales and Marketing Elan, Theravance, royalty pharma
Elan has struck a novel deal with Theravance which gives it a share of potential future royalties from its respiratory …
Elan sceptical of Royalty
February 26, 2013Sales and Marketing Elan, FDA, Tysabri, royalty pharma
Elan Corporation has poured tepid water on private equity firm Royalty Pharma’s putative offer this week for the Irish biotech …
Biogen and Elan file for Tysabri first line use in MS
January 18, 2013Sales and Marketing Biogen IDEC, EMA, Elan, FDA, MS, Tsyabri, gilenya
Biogen Idec and Elan have applied to the FDA and EMA to expand Tysabri’s use in patients with relapsing forms …
Elan to spin off drug discovery arm
August 14, 2012Research and Development, Sales and Marketing Elan, Neotype Biosciences, Tysabri, multiple sclerosis
Elan Corporation is to spin off its drug discovery arm Neotype Biosciences to create a separate, quoted company by the …
Lonza to make Elan’s Alzheimer’s candidate
December 7, 2011Manufacturing and Production Abbott, Elan, Lonza
Elan has awarded a manufacturing contract to Lonza to supply the active pharmaceutical ingredient (API) for its small-molecule candidate Alzheimer’s …
Alkermes and Elan Drug Technologies complete merger
September 19, 2011Manufacturing and Production Alkermes, Elan, pharma manufacturing news
The contract manufacturing and development unit of Irish drugmaker Elan has completed a near-$1 billion merger with drug delivery specialist …
Elan signs $20m research deal with Proteostasis
May 25, 2011Research and Development Elan, Proteostasis, neurodegenerative diseases
Elan Corporation has signed a deal with US small molecule drug specialist Proteostasis Therapeutics to develop products for conditions such …
Elan sells formulations unit to Alkermes for $960m
May 10, 2011Manufacturing and Production Alkermes, Elan
Irish drugmaker Elan has finally found a buyer for its Elan Drug Technologies unit, which has been on and off …
Pharmaceutical manufacturing news in brief
February 15, 2011Manufacturing and Production Boehringer Ingelheim, DSM Biologics, Elan, Novasep
Irish drugmaker Elan has forged an alliance with Boehringer Ingelheim to develop and manufacture antibody-based therapeutics. Under the terms of …
Elan names Robert Ingram as new chairman
December 10, 2010Research and Development, Sales and Marketing Elan, appointment, research and development, sales and marketing
Elan has appointed former Glaxo Wellcome chief executive Robert Ingram as its chairman-designate. Ingram led Glaxo between 1997 and 2000 …
Latest content
FibroFind appoints Lee Borthwick as CEO
